DD-01 is under clinical development by D&D Pharmatech and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DD-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DD-01 overview
DD-01 is under development for the treatment of severe obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic steatohepatitis (NASH). It is a long-acting dual agonist of GLP-1 and glucagon receptors. It is administered through subcutaneous route and acts by targeting glucagon like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR). The drug candidate is developed based on D&D long-acting technology.
D&D Pharmatech overview
D&D Pharmatech is a biotechnology company that develops and manufactures drugs for the treatment of neurodegenerative and fibrotic diseases. It also engaged in research and diagnostics of central nervous system drug. D&D Pharmatech is headquartered in Seongnam, Gyeonggi, South Korea.
For a complete picture of DD-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
